8-K filing — StratCap Digital Infrastructure REIT, Inc.

Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days

Why Nutanix Stock Is Soaring Today

Nutanix stock surged 9.87% after reporting Q4 2026 results that beat analyst expectations with $757.1 million in revenue (16% YoY growth) and $0.60 diluted EPS versus $0.49 expected. The company also generated strong free cash flow of $277.6 million and provided optimistic fiscal 2027 guidance of $3.18-$3.23 billion in revenue and $850-$950 million in free cash flow.

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

Will Lululemon (LULU) Beat Estimates Again in Its Next Earnings Report?

Lululemon has demonstrated a strong track record of beating earnings estimates, with an average surprise of 3.22% over the last two quarters. The company has a positive Earnings ESP of +0.70% combined with a Zacks Rank #3 (Hold), suggesting a high probability of another earnings beat in its September 3, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time.

Is It Too Late to Buy TMC The Metals Company After Its 32% Rally?

TMC The Metals Company has gained 32% recently after narrowing losses in Q2, but faces significant challenges. With zero revenue, a dwindling cash pile lasting only 4-5 quarters, and no regulatory approval for seafloor mining, the company's future hinges on obtaining a U.S. commercial recovery permit expected by late 2027. While global demand for critical metals supports long-term potential, substantial regulatory and international opposition risks remain.

Hormel Foods Q3 Earnings Beat on Margin Expansion, Sales Miss

Hormel Foods reported Q3 adjusted EPS of 37 cents, beating consensus estimates, but net sales fell 2.4% to $2.96B, missing expectations. The company expanded operating margins by 60 basis points despite volume declines across segments. Hormel lowered fiscal 2026 sales guidance to $12.1-$12.2B but raised EPS guidance to $1.45-$1.51, reflecting a Brazil divestiture and challenging external environment.